Teza Capital Management LLC Acquires 11,107 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Teza Capital Management LLC increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 74.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,065 shares of the company’s stock after purchasing an additional 11,107 shares during the period. Teza Capital Management LLC’s holdings in Intellia Therapeutics were worth $304,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in NTLA. Tema Etfs LLC bought a new stake in Intellia Therapeutics in the fourth quarter valued at $1,728,000. Second Line Capital LLC acquired a new stake in shares of Intellia Therapeutics in the 4th quarter valued at about $1,529,000. Shell Asset Management Co. increased its position in Intellia Therapeutics by 45.7% in the 4th quarter. Shell Asset Management Co. now owns 29,975 shares of the company’s stock valued at $350,000 after buying an additional 9,403 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new position in Intellia Therapeutics during the 4th quarter worth approximately $263,000. Finally, Sphera Funds Management LTD. raised its stake in Intellia Therapeutics by 60.1% during the 4th quarter. Sphera Funds Management LTD. now owns 466,080 shares of the company’s stock worth $5,434,000 after buying an additional 175,000 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $9.67 on Wednesday. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.18. The firm has a 50-day moving average price of $7.98 and a two-hundred day moving average price of $10.68. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -1.78 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. The business’s revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the company earned ($1.12) earnings per share. As a group, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Analysts Set New Price Targets

NTLA has been the subject of a number of research reports. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research report on Tuesday. Wedbush restated a “neutral” rating and set a $10.00 price target on shares of Intellia Therapeutics in a research note on Monday. Wells Fargo & Company dropped their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, Chardan Capital reiterated a “buy” rating and set a $68.00 price objective on shares of Intellia Therapeutics in a report on Friday, May 9th. Two analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $36.90.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.